Could CAR t cells slow progressive MS? early trial underway
NCT ID NCT06451159
First seen Feb 01, 2026 · Last updated May 24, 2026 · Updated 17 times
Summary
This early-phase study tests a new treatment called KYV-101 in 10 people with progressive multiple sclerosis (MS) whose disease has not responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and potentially calm the immune attack on the nervous system. The main goals are to find a safe dose and see if the therapy can reach the brain and spinal fluid.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROGRESSIVE MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California, San Francisco, Multiple Sclerosis Center
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.